Reading Room

Raptiva® Withdrawn From Market for High Risk of Fatal Brain Disease

Jon 6696

We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.

On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
 

Raptiva® Withdrawn From Market for High Risk of Fatal Brain Disease

Jon 6703

We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.

On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
 

Hydroxycut® Products Withdrawn From Market After FDA Consumer Advisory Warning

Jon 6469

Jon L. Gelman  is investigating potential cases involving users of Hydroxycut® products who have experienced health problems that may include Rhabdomyolysis (muscle damage that can lead to kidney failure and other health problems), death, cardiovascular symptoms, hypertension, elevated liver enzymes that can indicate liver failure, kidney failure and seizures. 

Hydroxycut® Products Withdrawn From Market After FDA Consumer Advisory Warning

Jon 6475

Jon L. Gelman  is investigating potential cases involving users of Hydroxycut® products who have experienced health problems that may include Rhabdomyolysis (muscle damage that can lead to kidney failure and other health problems), death, cardiovascular symptoms, hypertension, elevated liver enzymes that can indicate liver failure, kidney failure and seizures. 

First89101113151617Last

CONTACT US
1.973.696.7900
jon@gelmans.com